Please ensure Javascript is enabled for purposes of website accessibility

3 Dividend Stocks to Buy and Hold Forever

By Keith Speights – Sep 12, 2021 at 5:55AM

Key Points

  • One is a Dividend Aristocrat with several products that are delivering strong sales growth.
  • Another is a leader in the rapidly expanding renewable energy market.
  • The third great dividend stock is a healthcare giant that's both stable and nimble.

Motley Fool Issues Rare “All In” Buy Alert

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

They all have solid dividends plus attractive growth prospects.

What's the easiest way to increase your investment returns? Stretch out how long you hold onto your stocks. That's especially the case with dividend stocks. Reinvesting dividends over a long period of time can significantly boost your total returns.

If you intend to hold for a long time, though, it means that you'll want to be more selective about the stocks you buy in the first place. Here are three dividend stocks you can buy and hold forever.

A piggy bank with an infinity symbol on it.

Image source: Getty Images.

Abbott Laboratories

Abbott Laboratories (ABT 0.89%) is a Dividend Aristocrat with 49 consecutive years of dividend increases. The company ranks among Fortune's Top 50 Most Admired Companies. It's held the No. 1 spot in its industry for the last eight years.

Those are certainly impressive accolades. However, it's even more important that Abbott commands the market-leading position in all of its businesses. Cardiovascular care, diabetes care, diagnostics, nutrition -- you name it, and Abbott sits at the top.

Granted, Abbott's dividend yield of 1.4% probably won't make your mouth water. But the dividend will almost certainly grow over time. Even better, Abbott should deliver strong revenue and earnings growth that's a precursor to strong share price appreciation.

The company's FreeStyle Libre continuous glucose monitoring device and MitraClip mitral valve continue to serve as key growth drivers. Its COVID-19 testing sales could decline but should remain an important revenue source even after the pandemic ends. Abbott's commitment to innovation will likely translate to new products and new markets over the next decade and beyond. 

Brookfield Renewable

Brookfield Renewable (BEP 0.31%) (BEPC 0.50%) can't claim the track record of dividend hikes that Abbott can. However, the company has increased its dividend distribution by a compound annual growth rate of 6% over the last two decades. And most investors will probably like its yield of close to 3%.

There's one thing that Brookfield Renewable has in common with Abbott, though. Its growth prospects are even more attractive than its dividend.

Nearly 130 governments have established net-zero carbon emission targets. Close to 3,100 businesses have committed to slashing their carbon emissions by 50% by 2030. This presents a huge opportunity for Brookfield Renewable, which stands out as one of the world's leading renewable energy providers.  

Brookfield Renewable expects to generate total returns of between 12% and 15% over the long term. With the expanding demand for renewable energy and its massive development pipeline poised to provide significantly more capacity, the company should be in a strong position to achieve that goal. 

Johnson & Johnson

Few companies can boast as impressive a pedigree as Johnson & Johnson (JNJ 0.13%). It's a Dividend King with 59 consecutive years of dividend increases. J&J ranks No. 1 among pharmaceutical companies on Fortune's Most Admired Companies list. It's the largest healthcare company in the world. 

Johnson & Johnson is about as steady as they come. Roughly 70% of its sales come from products that are either No. 1 or No. 2 in their respective markets. The company has 28 products or platforms that generate annual sales of more than $1 billion. 

It's also a surprisingly nimble giant. The company has delivered an annualized total return of 13.1% over the last 10 years. Around one-fourth of its total revenue stems from products that have been launched in the past five years. 

J&J should be able to generate solid long-term earnings growth. Add to that the company's attractive dividend, which currently yields close to 2.8%. This blue-chip dividend stock is one that you'll probably never regret buying.

Keith Speights owns shares of Brookfield Renewable Corporation Inc. and Brookfield Renewable Partners L.P. The Motley Fool recommends Johnson & Johnson. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Johnson & Johnson Stock Quote
Johnson & Johnson
JNJ
$177.24 (0.13%) $0.23
Abbott Laboratories Stock Quote
Abbott Laboratories
ABT
$106.96 (0.89%) $0.94
Brookfield Renewable Partners L.P. Stock Quote
Brookfield Renewable Partners L.P.
BEP
$29.20 (0.31%) $0.09
Brookfield Renewable Corporation Inc. Stock Quote
Brookfield Renewable Corporation Inc.
BEPC
$32.32 (0.50%) $0.16

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
356%
 
S&P 500 Returns
118%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/27/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.